anabolic

By Targets:	Amino Acid Derivatives (2) Androgen Receptor (1) CDK (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (2) IGF-1R (3) Progesterone Receptor (1) Prostaglandin Receptor (1) Thyroid Hormone Receptor (2) Wnt (2)
By Research Areas:	Endocrinology (2) Inflammation/Immunology (5) Metabolic Disease (14)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122025

AC-262536 1 Publications Verification	Androgen Receptor	Metabolic Disease
AC-262536 is a selective and non-steroidal androgen receptor modulators (SARMs) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor, with an affinity in the low nanomolar range (1-10 nM) .

HY-145121

DS96432529

CDK Metabolic Disease

DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.

DS96432529	CDK	Metabolic Disease
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.

HY-146056

Anabolic agent-1	Others	Others
Compounds, as a new type of bone morphogenetic protein-2 up regulator, can not only correct the bone loss in patients, but also have a wide range of clinical applicability.

HY-W703425

17α-Ethynyl-19-nor-Δ-5(6)-androsten-17β-ol-3-one delta-5(6)-Norethindrone	Progesterone Receptor	Endocrinology
17α-Ethynyl-19-nor-Δ-5(6)-androsten-17β-ol-3-one (delta-5(6)-Norethindrone), an impurity of Norethindrone, is an anabolic agent. Norethindrone is a progestin athat can be used for endometriosis research .

HY-118608

2α-Methyl androsterone

Others Metabolic Disease

2α-Methyl androsterone is an anabolic androgenic steroid metabolite of mesterolone and drostanolone .

2α-Methyl androsterone	Others	Metabolic Disease
2α-Methyl androsterone is an anabolic androgenic steroid metabolite of mesterolone and drostanolone .

HY-114974

Rivenprost ONO-4819; ONO-AE1-734	Prostaglandin Receptor	Others Inflammation/Immunology
Rivenprost (ONO-4819; ONO-AE1-734) is a selective agonist for prostaglandin E receptor EP4 with K_i of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects .

HY-B1192S

Estradiol benzoate-d3 β-Estradiol 3-benzoate-d₃; 17β-Estradiol 3-benzoate-d₃	Estrogen Receptor/ERR
Estradiol benzoate-d₃ is the deuterium labeled Estradiol benzoate. Estradiol Benzoate (β-Estradiol 3-benzoate), a proagent of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability[1][2][3][4].

HY-P1773A

IGF-I (30-41) (TFA) Insulin-like Growth Factor I (30-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .

HY-N6678

Zearalanone 1 Publications Verification	Estrogen Receptor/ERR	Endocrinology
Zearalenone is a nonsteroidal estrogenic mycotoxin produced by Fusarium species, which colonizes several grains. Zearalenone has low acute toxicity and carcinogenicity. Due to its agonistic effect on the estrogen receptor, Zearalenone exhibits distinct estrogenic and anabolic properties in several animal species, resulting in severe effects on the reproductive system .

HY-112102

(22S,23S)-Homobrassinolide SSHB	Others	Metabolic Disease
(22S,23S)-Homobrassinolide is one of the most active brassinosteroids in inducing plant growth in various plant bioassay systems. (22S,23S)-Homobrassinolide shows Akt-dependent anabolic activity in rat skeletal muscle cells. Orally active .

HY-P2832

Acyl coenzyme A synthetase ACS	Endogenous Metabolite	Metabolic Disease
Acyl coenzyme A synthetase (ACS), namely acetyl coenzyme A synthetase, is often used in biochemical research. Acyl coenzyme A synthetase can catalyze the activation of fatty acids by coenzyme A through a two-step thioesterification reaction to produce acyl coenzyme A, and then participate in a variety of anabolic and catabolic lipid metabolism pathways, and participate in the TCA cycle in aerobic respiration .

HY-N1993

5-Methyl-7-methoxyisoflavone 1 Publications Verification
5-Methyl-7-methoxyisoflavone is a non-steroidal anabolic isoflavone. 5-Methyl-7-methoxyisoflavone shows potency increasing muscle mass and endurance. 5-Methyl-7-methoxyisoflavone can be used for fat loss, increase vitality and muscle gain besides the maintenance of low cholesterol level and strengthen bones .

HY-124156

KY-02327	Wnt	Metabolic Disease
KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .

HY-124156A

KY-02327 acetate	Wnt	Metabolic Disease
KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .

HY-P1777

IGF-I (24-41) Insulin-like Growth Factor I (24-41)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .

HY-P3497

Fmoc-Cys-Asp10	Amino Acid Derivatives	Others
Fmoc-Cys-Asp10 is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .

HY-P3497A

Fmoc-Cys-Asp10 TFA	Amino Acid Derivatives	Others
Fmoc-Cys-Asp10 (TFA) is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .

HY-P1777A

IGF-I (24-41) (TFA) Insulin-like Growth Factor I (24-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .

HY-P1252A

Parathyroid Hormone (1-34), bovine TFA	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

HY-P1252

Parathyroid Hormone (1-34), bovine 1 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	898 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 898 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

898 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 898 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Type

HY-P2832

Acyl coenzyme A synthetase ACS	Biochemical Assay Reagents
Acyl coenzyme A synthetase (ACS), namely acetyl coenzyme A synthetase, is often used in biochemical research. Acyl coenzyme A synthetase can catalyze the activation of fatty acids by coenzyme A through a two-step thioesterification reaction to produce acyl coenzyme A, and then participate in a variety of anabolic and catabolic lipid metabolism pathways, and participate in the TCA cycle in aerobic respiration .

Acyl coenzyme A synthetase

ACS

Biochemical Assay Reagents

Acyl coenzyme A synthetase (ACS), namely acetyl coenzyme A synthetase, is often used in biochemical research. Acyl coenzyme A synthetase can catalyze the activation of fatty acids by coenzyme A through a two-step thioesterification reaction to produce acyl coenzyme A, and then participate in a variety of anabolic and catabolic lipid metabolism pathways, and participate in the TCA cycle in aerobic respiration .

Cat. No.	Product Name	Target	Research Area

HY-P1777

IGF-I (24-41) Insulin-like Growth Factor I (24-41)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .

HY-P4838

pTH (2-38) (human)	Peptides	Others
pTH (2-38) (human) is involved in the anabolic action of bone. PTH (2-38) can increase the level of serum INS-PTH (complete N-terminal specific PTH) .

HY-P1773

IGF-I (30-41) Insulin-like Growth Factor I (30-41)	Peptides	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .

HY-P1773A

IGF-I (30-41) (TFA) Insulin-like Growth Factor I (30-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .

HY-P3497

Fmoc-Cys-Asp10	Amino Acid Derivatives	Others
Fmoc-Cys-Asp10 is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .

HY-P3497A

Fmoc-Cys-Asp10 TFA	Amino Acid Derivatives	Others
Fmoc-Cys-Asp10 (TFA) is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .

HY-P1777A

IGF-I (24-41) (TFA) Insulin-like Growth Factor I (24-41) (TFA)	IGF-1R	Metabolic Disease Inflammation/Immunology
IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .

HY-P1252A

Parathyroid Hormone (1-34), bovine TFA	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

HY-P1252

Parathyroid Hormone (1-34), bovine 1 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

Cat. No.	Product Name	Target	Research Area

HY-P99857

Domagrozumab PF-06252616	Inhibitory Antibodies	Metabolic Disease
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a K_D value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6678

Zearalanone 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Antibacterial Disease Research Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Anticancer Disease Research Fields Endocrinology	Estrogen Receptor/ERR
Zearalenone is a nonsteroidal estrogenic mycotoxin produced by Fusarium species, which colonizes several grains. Zearalenone has low acute toxicity and carcinogenicity. Due to its agonistic effect on the estrogen receptor, Zearalenone exhibits distinct estrogenic and anabolic properties in several animal species, resulting in severe effects on the reproductive system .

Cat. No.	Product Name	Chemical Structure

HY-B1192S

Estradiol benzoate-d3
Estradiol benzoate-d₃ is the deuterium labeled Estradiol benzoate. Estradiol Benzoate (β-Estradiol 3-benzoate), a proagent of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability[1][2][3][4].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

anabolic

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products